Clinical Trials Logo

Cholecystitis clinical trials

View clinical trials related to Cholecystitis.

Filter by:

NCT ID: NCT06315387 Recruiting - Cholecystitis Clinical Trials

Safety, Tolerability and Pharmacokinetics of 4-MUST, Tablets, 128 mg (Valenta Pharm JSC) During Single and Multiple Oral Administration in Healthy Volunteers

Start date: December 4, 2023
Phase: Phase 1
Study type: Interventional

Study of safety, tolerability and pharmacokinetic parameters of different doses of 4-MUST, tablets, 128 mg (Valenta Pharm JSC) in healthy volunteers

NCT ID: NCT06287112 Not yet recruiting - Acute Cholecystitis Clinical Trials

Prevention of Acute Cholecystitis With ETGBD

Start date: March 2, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about Efficacy of the ETGBD parallel insertion with fully covered self-expandable metal stent for preventing acute cholecystitis in patients with low cystic duct insertion. In this study, we hypothesized that endoscopic transpapillary gallbladder drainage (ETGBD) with parallel insertion of a fully covered self-expanding metal stent(FCSEMS) through an endoscopic biliary drainage tunnel is superior in preventing complications such as cholecystitis when the gallbladder ducts confluence within the distal third of the common bile duct. And we aimed to confirm its efficacy by comparing the frequency, severity, and rate of invasive additional procedures due to cholecystitis complications to provide evidence of clinical utility.

NCT ID: NCT06280404 Not yet recruiting - Clinical trials for Cholecystitis, Chronic

Body First Approach in Lap Cholecystectomy in Cases With Obscure Calot's Triangle

Start date: March 15, 2024
Phase:
Study type: Observational

The aim of this study is to evaluate the body first approach on the rate of conversion to open technique & VBI in patients with obscure calot's triangle.

NCT ID: NCT06264115 Enrolling by invitation - Clinical trials for Cholecystitis, Chronic

Outcomes of Three Ports Versus Four Ports Laparoscopic Cholecystectomy, Sohag General Surgery Department Experience

Start date: January 1, 2024
Phase:
Study type: Observational

To compare the outcomes of three ports and four ports Laparoscopic Cholecystectomy

NCT ID: NCT06244589 Completed - Cholelithiasis Clinical Trials

Evaluation of Risk Factors Leading to Conversion From Laparoscopic Cholecystectomy to Open Surgery

Start date: February 12, 2024
Phase: N/A
Study type: Interventional

This retrospective controlled study aims to evaluate risk factors that affect open conversion in laparoscopic cholecystectomy. Patient characteristics, medical history, biochemical and radiological studies of the patient will searched from the hospital database and factors affecting open conversion will be analysed.

NCT ID: NCT06228027 Not yet recruiting - Acute Cholecystitis Clinical Trials

External Validation os the ACME Scoring System

ACME_2
Start date: January 1, 2025
Phase:
Study type: Observational [Patient Registry]

Acute calculous cholecystitis (ACC) is the second most frequent surgical condition in emergency departments. The recommended treatment is surgical treatment (ST) and the accepted mortality is <1%, but in severe and/or fragile patients is higher. Despite the Tokyo Guidelines, there no consensus on who is the unfit patient for ST. A recent study has identified 4 risk factors that predicts the mortality in a 92% of patients (ACME) and could help to develop new guidelines in ACC. The aim of this study is to perfom an external validation of the new simplified scoring system for mortality in ACC.

NCT ID: NCT06227936 Not yet recruiting - Cholecystitis Clinical Trials

Complications of Cholecystostomy in ACC

Chole_ACC
Start date: May 15, 2024
Phase:
Study type: Observational

Acute cholecystitis (AC) is the second most frequent pathology in Surgical Emergencies; laparoscopic cholecystectomy (LC) is the gold standard treatment, but not all patients are fit for surgery at the diagnostic. Percutaneous Cholecystostomy (PC) is an alternative to LC but has high comorbidity. This study aims to analyse the complications of PC and review its indications in the literature.

NCT ID: NCT06224868 Not yet recruiting - Cholecystitis Clinical Trials

Comparison of the Effects of Different PEEP Values With USG on Optic Nerve Sheath Diameter

Start date: January 15, 2024
Phase: N/A
Study type: Interventional

Laparoscopic surgeries are now more popular because of the advantages such as shorter hospital stay, minimal scar. In order to perform laparoscopic surgery, pneumoperitoneum should be initiated. The optic nerve sheath is an extension of the dura mater and the subarachnoid space is continuous with the intracranial subarachnoid space. Therefore, non-invasive monitoring of the increase in intracranial pressure (ICP) can be achieved by measuring the optic nerve and sheath diameter with ultrasound. Since ONSD measurement with ultrasound is an easily applicable technique, it is useful in monitoring intracranial pressure changes based on the optic nerve diameter during intraoperative changes

NCT ID: NCT06213753 Completed - Acute Cholecystitis Clinical Trials

Complications of Non-Surgical Treatment in Acute Cholecystitis

Start date: January 2011
Phase:
Study type: Observational

Acute cholecystitis (AC) is the second most frequent pathology in Surgical Emergencies; laparoscopic cholecystectomy (LC) is the gold standard treatment, but not all patients are fit for surgery. Percutaneous Cholecystostomy (PC) is an alternative to LC but has high comorbidity. There is no protocol in our institution for Non-Surgical Treatment (NST). This study aims to analyse the complications of non-surgical treatment and a new local management algorithm

NCT ID: NCT06213740 Completed - Acute Cholecystitis Clinical Trials

Validation of a New Simplified Scoring System for Acute Calculous Cholecystitis

ACME
Start date: January 8, 2021
Phase:
Study type: Observational

Acute calculous cholecystitis (ACC) is the second most frequent surgical condition in emergency departments. The recommended treatment is surgical treatment (ST) and the accepted mortality is <1%, but in severe and/or fragile patients is higher. Despite the Tokyo Guidelines, there no consensus on who is the unfit patient for ST. A recent study has identified 4 risk factors that predicts the mortality in a 92% of patients (ACME) and could help to develop new guidelines in ACC. The aim of this study is this validation of the new simplified scoring system for mortality in ACC.